Sarah M. Bartsch

Sarah M. Bartsch

Auto-generated profile, based on publicly available information

Sarah M. Bartsch

Public Health Informatics, Computational, and Operations Research and Center for Advanced Technology and Communication in Health, City University of New York Graduate School of Public Health and Health Policy, New York City, NY, United States

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2024 in Vaccine
Verified
Journal Article
Open access
GYGavin Yamey
Gavin Yamey
KMKaci Kennedy McDade
Kaci Kennedy McDade
Sir Roy AndersonSir Roy Anderson
Sir Roy Anderson
SBSarah M. Bartsch
Sarah M. Bartsch
MBMaria Bottazzi
Maria Bottazzi
CMCaroline Marshall
Caroline Marshall
Schistosomiasis is caused by parasitic flatworms (Schistosoma). The disease in humans can be caused by seven different species of Schistosoma: S. mansoni, S. japonicum, S. haematobium, S. malayensis, S. mekongi, S. guineensis and S. intercalatum, as well as by hybrids between species, including livestock schistosome species. People are infected when exposed to infested water and the parasite larvae penetrate the skin. Poor and rural communities are typically the most affected, and the general population who lives in affected areas and is exposed to contaminated water is at risk. Areas with poor access to safe water and adequate sanitation are also at heightened risk. About 236.6 million people required treatment for schistosomiasis in 2019-mostly people living in poor, rural communities, especially fishing and agricultural communities. This 'Vaccine Value Profile' (VVP) for schistosomiasis is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic, and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations. All contributors have extensive expertise on various elements of the schistosomiasis VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.

17 June 2022 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
PMPatricia L Mabry
Patricia L Mabry
Nicolaas PronkNicolaas Pronk
Nicolaas Pronk
CAChristopher I. Amos
Christopher I. Amos
JWJohn S. Witte
John S. Witte
PWPatrick T. Wedlock
Patrick T. Wedlock
BLBruce Y. Lee
Bruce Y. Lee
Patricia Mabry and coauthors discuss application of systems approaches in cancer research.

7 January 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
BLBruce Y. Lee
Bruce Y. Lee
SBSarah M. Bartsch
Sarah M. Bartsch
MFMarie C. Ferguson
Marie C. Ferguson
PWPatrick T. Wedlock
Patrick T. Wedlock
KOKelly J. O’sHea
Kelly J. O’sHea
JMJames A. McKinnell
James A. McKinnell
Finding medications or vaccines that may decrease the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could potentially reduce transmission in the broader population. We developed a computational model of the U.S. simulating the spread of SARS-CoV-2 and the potential clinical and economic impact of reducing the infectious period duration. Simulation experiments found that reducing the average infectious period duration could avert a median of 442,852 [treating 25% of symptomatic cases, reducing by 0.5 days, reproductive number (R0) 3.5, and starting treatment when 15% of the population has been exposed] to 44.4 million SARS-CoV-2 cases (treating 75% of all infected cases, reducing by 3.5 days, R0 2.0). With R0 2.5, reducing the average infectious period duration by 0.5 days for 25% of symptomatic cases averted 1.4 million cases and 99,398 hospitalizations; increasing to 75% of symptomatic cases averted 2.8 million cases. At $500/person, treating 25% of symptomatic cases saved $209.5 billion (societal perspective). Further reducing the average infectious period duration by 3.5 days averted 7.4 million cases (treating 25% of symptomatic cases). Expanding treatment to 75% of all infected cases, including asymptomatic infections (R0 2.5), averted 35.9 million cases and 4 million hospitalizations, saving $48.8 billion (societal perspective and starting treatment after 5% of the population has been exposed). Our study quantifies the potential effects of reducing the SARS-CoV-2 infectious period duration.